Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check3 days agoChange DetectedRecruitment status was updated to 'No longer looking for participants', indicating enrollment is closed. The page also adds new help sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and updates the revision to v3.6.0, along with changing the label from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.2%

- Check10 days agoChange DetectedThe page revision label has been updated from v3.5.4 to v3.5.5. This appears to be a minor version update for the page documentation and related text.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated the page's revision history to include Revision: v3.5.4 and remove Revision: v3.5.3, reflecting the latest document version.SummaryDifference0.0%

- Check46 days agoChange DetectedThe Taoyuan District listing was replaced with Taoyuan, reflecting a city-level designation with the same postal code 33305. This aligns the location with the actual site and improves accuracy for recruitment and contact information.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page’s displayed software/site revision indicator has been updated from v3.5.0 to v3.5.3. This represents a maintenance/frontend version change rather than an update to the clinical trial information presented.SummaryDifference0.0%

- Check89 days agoChange DetectedSite listing updated from Napoli, Italy, 80131 to Naples, Italy, 80131. Page revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.